Free Trial

argenex (ARGX) Stock Price, News & Analysis

argenex logo
$540.71 -10.51 (-1.91%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$541.00 +0.28 (+0.05%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About argenex Stock (NASDAQ:ARGX)

Key Stats

Today's Range
$540.37
$550.39
50-Day Range
$532.27
$656.65
52-Week Range
$377.48
$678.21
Volume
479,363 shs
Average Volume
324,937 shs
Market Capitalization
$33.02 billion
P/E Ratio
33.36
Dividend Yield
N/A
Price Target
$709.18
Consensus Rating
Buy

Company Overview

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

ARGX MarketRank™: 

argenex scored higher than 86% of companies evaluated by MarketBeat, and ranked 327th out of 1,880 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    argenex has received a consensus rating of Buy. The company's average rating score is 3.05, and is based on 19 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    argenex has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about argenex's stock forecast and price target.
  • Earnings Growth

    Earnings for argenex are expected to grow by 246.65% in the coming year, from $3.13 to $10.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of argenex is 33.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.41.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of argenex is 33.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.94.

  • Price to Earnings Growth Ratio

    argenex has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    argenex has a P/B Ratio of 5.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about argenex's valuation and earnings.
  • Percentage of Shares Shorted

    3.56% of the float of argenex has been sold short.
  • Short Interest Ratio / Days to Cover

    argenex has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in argenex has recently decreased by 12.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    argenex does not currently pay a dividend.

  • Dividend Growth

    argenex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.56% of the float of argenex has been sold short.
  • Short Interest Ratio / Days to Cover

    argenex has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in argenex has recently decreased by 12.08%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    argenex has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for argenex this week, compared to 10 articles on an average week.
  • Search Interest

    11 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added argenex to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, argenex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.43% of the stock of argenex is held by insiders.

  • Percentage Held by Institutions

    60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about argenex's insider trading history.
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenex and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

argenx (NASDAQ:ARGX) Given "Buy" Rating at HC Wainwright
Something very strange is happening...
What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone noticed when the U.S. Senate granted sweeping powers to a Harvard economist who has some dangerous ideas about the U.S. dollar. Now, he's issued a blueprint for what a coming "Mar-a-Lago Accord" could look like. One analyst who predicted the 2008 crisis says this plan could see the dollar fall in value by 40% in months and become a national nightmare.
argenx SE (ARGX): A Bull Case Theory
Argenx added to Best Ideas List at Wedbush
See More Headlines

ARGX Stock Analysis - Frequently Asked Questions

argenex's stock was trading at $615.00 at the beginning of 2025. Since then, ARGX shares have decreased by 12.1% and is now trading at $540.71.
View the best growth stocks for 2025 here
.

argenex SE (NASDAQ:ARGX) announced its quarterly earnings results on Thursday, May, 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The firm earned $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenex had a net margin of 40.20% and a trailing twelve-month return on equity of 16.15%.
Read the conference call transcript
.

argenex (ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Top institutional investors of argenex include Price T Rowe Associates Inc. MD (8.82%), Wellington Management Group LLP (0.67%), Invesco Ltd. (0.63%) and Lord Abbett & CO. LLC (0.45%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that argenex investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Last Earnings
5/08/2025
Today
6/17/2025
Next Earnings (Estimated)
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED-BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
1,599
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$709.18
High Stock Price Target
$1,065.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+31.2%
Consensus Rating
Buy
Rating Score (0-4)
3.05
Research Coverage
22 Analysts

Profitability

Trailing P/E Ratio
91.87
Forward P/E Ratio
172.75
P/E Growth
0.96
Net Income
$833.04 million
Pretax Margin
13.67%

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$2.78 per share
Price / Cash Flow
194.54
Book Value
$90.49 per share
Price / Book
5.98

Miscellaneous

Free Float
59,576,000
Market Cap
$33.02 billion
Optionable
Optionable
Beta
0.39
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ARGX) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners